Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 276

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies

Open access
Rawat, Kajal, Kumari, Puja, Saha, Lekha·2021·European Journal of Pharmacology

Abstract

Coronavirus Disease 2019 named as COVID-19 imposing a huge burden on public health as well as global economies, is caused by a new strain of betacoronavirus named as SARS-CoV-2. The high transmission rate of the virus has resulted in current havoc which highlights the need for a fast and effective approach either to prevent or treat the deadly infection. Development of vaccines can be the most prominent approach to prevent the virus to cause COVID-19 and hence will play a vital role in controlling the spread of the virus and reducing mortality. The virus uses its spike proteins for entering into the host by interacting with a specific receptor called angiotensin converting enzyme-2 (ACE2) present on the surface of alveolar cells in the lungs. Researchers all over the world are targeting the spike protein for the development of potential vaccines. Here, we discuss the immunopathological basis of vaccine designing that can be approached for vaccine development against SARS-CoV-2 infection and different platforms that are being used for vaccine development. We believe this review will increase our understanding of the vaccine designing against SARS-CoV-2 and subsequently contribute to the control of SARS-CoV-2 infections. Also, it gives an insight into the current status of vaccine development and associated outcomes reported at different phases of trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejphar.2020.173751

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 93 references

Research works printed but not linked: 8

  1. Becker, 2020, 50, 499
  2. Geiben-Lynn, 2008, Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses, Clin. Vaccine Immunol., 15, 691, 10.1128/CVI.00418-07 · doi:10.1128/cvi.00418-07
  3. Gyawali, 2020, A review on ayurvedic medicinal herbs as remedial perspective for COVID-19, J. Karnali Acad. Heal. Sci., 3, 1
  4. Kim, 2009, DNA vaccines against Influenza viruses, Vaccines Pandemic Influ, 333, 197, 10.1007/978-3-540-92165-3_10 · doi:10.1007/978-3-540-92165-3_10
  5. Leung, 2007, The efficacy of Chinese medicine for SARS: a review of Chinese publications after the crisis, Am. J. Chin. Med., 35, 575, 10.1142/S0192415X07005077 · doi:10.1142/s0192415x07005077
  6. Roncati, 2020, Signals of Th2 immune response from COVID-19 patients requiring intensive care, Ann. Hematol., 99, 1419, 10.1007/s00277-020-04066-7 · doi:10.1007/s00277-020-04066-7
  7. Soruban, 2020, Comparative study on pandemic crisis - Covid19 and Sri Lankan Siddha system of medicine – a literature review, EJPMR, 7, 292
  8. Zhang, 2020, The continuous evolution and dissemination of 2019 novel human Coronavirus, J. Infect., 20, 1

Cited by

See all 276

Metadata

Authors
Rawat, K., Kumari, P., & Saha, L.
Venue
European Journal of Pharmacology
Publisher
Elsevier BV
Published
2021-02
Volume
892
Pages
173751
ISSN
0014-2999 (ISSN-L)
OpenAlex
W3108894477
Cited by
276
References
93
FWCI
7.85
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. https://app.cochat.ai/papers/10.1016/j.ejphar.2020.173751
The paper
Rawat, K., Kumari, P., & Saha, L. (2021). COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2020.173751

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.